Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

$1.25 Million Awarded To Prostate Cancer Research
New treatments to ease or even cure the most common cancer affecting Australian men are a step closer to reality with a $1.25 million grant awarded to QUT prostate cancer researcher Professor Colleen Nelson today.

Reports From The White House And Kaiser Family Foundation Address Health Care Disparities
Health and Human Services Secretary Kathleen Sebelius and White House Health Czar Nancy Ann DeParle held a discussion of minority health issues at the White House yesterday, where Sebelius "said the Obama administration is committed to addressing the "alarming disparity in the delivery of quality health care"," which she said was necessary to lower costs, the Associated Press reports. The White House also "issued a summary report on minority health care showing that African-Americans are seven times more likely as whites to have HIV/AIDS, that blacks and Hispanics have diabetes rates nearly twice as high as whites, and that black men are 50 percent more likely than whites to have prostate cancer" (Evans, 6/9).
News of the day
Drugs Can Eliminate River Blindness, Study Finds
The disease onchocerciasis, also known as river blindness, can be eliminated using drugs, according to a WHO study, BBC reports. The disease, which infects about 37 million people worldwide, is caused by a "nematode worm that can live inside the human body for years" and is transmitted to people through the bite of a black fly, the news service writes. The worms spread through the body and when they eventually die, the human immune system "reacts fiercely," which "destroys living tissue - especially the eye," according to BBC (7/21).
Health Insurance

Team Develops Anti-Infection Technology

Combat-related injuries have long plagued the military in part because of multidrug-resistant bacteria. Imagine being able to spray a compound fracture with microcapsules that deliver a drug to bolster the immune system, stopping infection before it starts. That technology might be around the corner, says Bingyun Li, Ph.D., of the West Virginia University Department of Orthopaedics and director of the WVU Biomaterials, Bioengineering & Nanotechnology Laboratory. Li"s team has developed a drug-delivery technology involving microcapsules - and a second technique, nanocoating - that have been shown to work in animal studies. Results of the team"s research involving the drug interleukin-12, a drug currently in anti-cancer clinical trials, has been published in the May issue of the journal Biomaterials. A deeper explanation of the approach, which could develop into an alternative to antibiotic therapy, is scheduled to be published in an upcoming issue of the Journal of Orthopaedic Research. "These pioneering techniques could be important to the United States because of the wars in Iraq and Afghanistan," Li says. "The treatment of battlefield casualties is expensive, and the infection rate runs from 2 percent to 15 percent. In some cases, because the organisms have developed resistance, antibiotics don"t work." Outside the arena of warfare, millions of people could potentially be helped by the technology because infections can result whenever a biomedical device is implanted. Li"s team developed two ways to deliver interleukin-12. The first is in microcapsules that can be injected or, potentially, delivered in a fine-mist spray directly to the site of an injury. The second is a nanocoating of interleukin-12 applied directly to stents, pacemakers, pain pumps, artificial limbs - virtually any biomedical device - before implantation. The coating is measured on the nano scale; one nanometer is one billionth of a meter. "Interleukin-12 will maximize the body"s natural response to an extent where infections can be prevented without the risk of the offending bacteria developing resistance to the treatment, as is becoming more of a problem with antibiotic therapy alone. With nanocoating, the drug is right where it needs to be - at the interface of the implant and your tissue," Li said. "With the microcapsule, the drug can be injected or sprayed where desired, and the nanocoating and microcapsule prolong the half-life of interleukin-12." In both methods, because the interleukin-12 is delivered locally rather than spread throughout the body, as in antibiotic therapy, side effects are minimal, Li explained. Li drew his team from the WVU Department of Orthopaedics, the WVU School of Pharmacy, the National Institute for Occupational Health and Safety (NIOSH), and the WVU Department of Microbiology, Immunology and Cell Biology. Li, who is also a guest researcher with NIOSH, is giving a presentation on the technology later this summer to officials from the Naval Medical Research Center in Silver Spring, Maryland. He is also working with Christopher Kolanko, Ph.D., a Department of Defense consultant for the WVU Research Corporation, and program managers with the Department of Defense, to discuss further research possibilities and possible military applications. Li"s team has spent the past four years developing the technology, funded in part by the WVU Research Corporation, the National Science Foundation and the Osteosynthesis and Trauma Care Foundation. West Virginia University Health Sciences Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009